Clinafloxacin CI96 AM1091CAS# 105956-97-6 |
- Pemirolast potassium
Catalog No.:BCC4532
CAS No.:100299-08-9
- Desloratadine
Catalog No.:BCC4540
CAS No.:100643-71-8
- Clemastine Fumarate
Catalog No.:BCC4528
CAS No.:14976-57-9
- Hydroxyzine 2HCl
Catalog No.:BCC4519
CAS No.:2192-20-3
- Loratadine
Catalog No.:BCC1262
CAS No.:79794-75-5
- Brompheniramine hydrogen maleate
Catalog No.:BCC4515
CAS No.:980-71-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 105956-97-6 | SDF | Download SDF |
| PubChem ID | 60063 | Appearance | Powder |
| Formula | C17H17ClFN3O3 | M.Wt | 365.8 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | PD 127391 | ||
| Solubility | DMSO : 2 mg/mL (5.47 mM; ultrasonic and warming and heat to 80°C) | ||
| Chemical Name | 7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid | ||
| SMILES | C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)Cl)N4CCC(C4)N)F)C(=O)O | ||
| Standard InChIKey | QGPKADBNRMWEQR-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Clinafloxacin(PD-127391) is a fluoroquinolone antibiotic.
Target: Antibacterial
Clinafloxacin is a broad-spectrum antibiotic of the quinolone carboxylic acid category currently in development for intravenous and oral therapy of serious infections [1]. Clinafloxacin is a novel fluoroquinolone with potent broad-spectrum in vitro activity against gram-positive, gram-negative, and anaerobic pathogens. Clinafloxacin is highly active against S. pneumoniae 7785 (MIC, 0.125 μg/mL), and neither gyrA nor parC quinolone resistance mutations alone have much effect on this activity [2]. Clinafloxacin is identified as the most active fluoroquinolone against S. pneumoniae when compared with ofloxacin, levofloxacin, sparfloxacin, grepafloxacin, and trovafloxacin and is currently being evaluated as an antipneumococcal agent [3]. References: | |||||
Clinafloxacin CI96 AM1091 Dilution Calculator
Clinafloxacin CI96 AM1091 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7337 mL | 13.6687 mL | 27.3373 mL | 54.6747 mL | 68.3434 mL |
| 5 mM | 0.5467 mL | 2.7337 mL | 5.4675 mL | 10.9349 mL | 13.6687 mL |
| 10 mM | 0.2734 mL | 1.3669 mL | 2.7337 mL | 5.4675 mL | 6.8343 mL |
| 50 mM | 0.0547 mL | 0.2734 mL | 0.5467 mL | 1.0935 mL | 1.3669 mL |
| 100 mM | 0.0273 mL | 0.1367 mL | 0.2734 mL | 0.5467 mL | 0.6834 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Clinafloxacin is a fluoroquinolone that inhibits both Topo II (DNA gyrase)and topoisomerase IV dually in Streptococcus pneumoniae.
- OLDA
Catalog No.:BCC7138
CAS No.:105955-11-1
- STEARDA
Catalog No.:BCC7288
CAS No.:105955-10-0
- Doxycycline HCl
Catalog No.:BCC3772
CAS No.:10592-13-9
- Taraxasterol
Catalog No.:BCN5869
CAS No.:1059-14-9
- (tert-Butoxycarbonyl)oxycefcapene pivoxil
Catalog No.:BCC8403
CAS No.:105889-80-3
- Obtusilin
Catalog No.:BCN2697
CAS No.:105870-59-5
- TSTU
Catalog No.:BCC2828
CAS No.:105832-38-0
- Tropisetron Hydrochloride
Catalog No.:BCC4027
CAS No.:105826-92-4
- Nateglinide
Catalog No.:BCC5005
CAS No.:105816-04-4
- E-3810
Catalog No.:BCC1541
CAS No.:1058137-23-7
- Sitostenone
Catalog No.:BCN5868
CAS No.:1058-61-3
- Fmoc-Ser(tBu)-OPfp
Catalog No.:BCC3545
CAS No.:105751-13-1
- Sulfocostunolide B
Catalog No.:BCN5870
CAS No.:1059671-65-6
- 2-(3,4-Dihydroxyphenyl)ethanol
Catalog No.:BCN5871
CAS No.:10597-60-1
- Geraniol
Catalog No.:BCN2631
CAS No.:106-24-1
- Nerol
Catalog No.:BCN8517
CAS No.:106-25-2
- β-Interleukin I (163-171), human
Catalog No.:BCC1017
CAS No.:106021-96-9
- Palmatine hydrochloride
Catalog No.:BCN5914
CAS No.:10605-02-4
- Hoechst 33342 analog 2
Catalog No.:BCC1631
CAS No.:106050-84-4
- Senktide
Catalog No.:BCC6921
CAS No.:106128-89-6
- PND-1186
Catalog No.:BCC1866
CAS No.:1061353-68-1
- TC-G 1004
Catalog No.:BCC6165
CAS No.:1061747-72-5
- WAY-600
Catalog No.:BCC4607
CAS No.:1062159-35-6
- WYE-687
Catalog No.:BCC4604
CAS No.:1062161-90-3
Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.[Pubmed:26722110]
Antimicrob Agents Chemother. 2015 Dec 31;60(1):1-5.
Respiratory infection with Burkholderia cenocepacia is associated with accelerated decline in lung function and increased mortality in cystic fibrosis (CF) patients (A. M. Jones, M. E. Dodd, J. R. W. Govan, V. Barcus, C. J. Doherty, J. Morris, and A. K. Webb, Thorax 59:948-951, 2004, http://dx.doi.org/10.1136/thx.2003.017210). B. cenocepacia often possesses innate resistance to multiple antimicrobial classes, making eradication uncommon in established infection (P. B. Davis, Am J Respir Crit Care Med 173:475-482, 2006, http://dx.doi.org/10.1164/rccm.200505-840OE). We report the use of clinafloxacin in a CF patient with advanced B. cenocepacia infection, present pharmacokinetic (PK) data, and discuss the potential therapeutic role of clinafloxacin in patients with this condition.
Heterologous strategy enhancing the sensitivity of the fluorescence polarization immunoassay of clinafloxacin in goat milk.[Pubmed:25914021]
J Sci Food Agric. 2016 Mar 15;96(4):1341-6.
BACKGROUND: Clinafloxacin is used for the treatment of disease in food-producing animals, e.g. Brucella melitensis, which often occurs in goats; however, the clinafloxacin residue in goat milk may harm human health and result in the development of drug-resistant bacterial strains or allergies. Despite this, there is not a rapid, sensitive and accurate analytical method in goat milk for rapid screening or monitoring purposes. RESULTS: One homologous and five heterologous tracers were designed and compared for fluorescence polarization immunoassay (FPIA) optimization. Based on the combination of a heterologous tracer (PAZ-FITC, synthesized with pazufloxacin and FITC) and the antibody against clinafloxacin, a highly sensitive FPIA was established for the detection of clinafloxacin residue in goat milk for the first time. The IC50 value was 29.3 microg L(-1) for clinafloxacin in the heterologous format - six times lower than that of the combination of the homologous tracers and the antibody. The recoveries ranged from 86.8% to 104.5%, with the relative standard deviation ranging from 4.1% to 7.2%. Validation by high-performance liquid chromatography (HPLC) confirmed that the results obtained from the proposed FPIA were in agreement with those of HPLC. CONCLUSION: This proposed heterologous strategy for enhanced FPIA is sensitive and rapid enough for the high-throughput detection of clinafloxacin residue in goat milk.
In vitro activity and rodent efficacy of clinafloxacin for bovine and swine respiratory disease.[Pubmed:23785362]
Front Microbiol. 2013 Jun 14;4:154.
Clinafloxacin is a broad-spectrum fluoroquinolone that was originally developed and subsequently abandoned in the late 1990s as a human health antibiotic for respiratory diseases. The purpose of this study was to investigate the activity of clinafloxacin as a possible treatment for respiratory disease in cattle and pigs. Minimum inhibitory concentration (MIC) values were determined using Clinical and Laboratory Standards Institute recommended procedures with recent strains from the Zoetis culture collection. Rodent efficacy was determined in CD-1 mice infected systemically or intranasally with bovine Mannheimia haemolytica or Pasteurella multocida, or swine Actinobacillus pleuropneumoniae, and administered clinafloxacin for determination of ED50 (efficacious dose-50%) values. The MIC90 values for clinafloxacin against bovine P. multocida, M. haemolytica, Histophilus somni, and M. bovis were 0.125, 0.5, 0.125, and 1 mug/ml, respectively, and the MIC90 values against swine P. multocida, A. pleuropneumoniae, S. suis, and M. hyopneumoniae were i0.03, i0.03, 0.125, and i0.008 mug/ml, respectively. Efficacy in mouse models showed average ED50 values of 0.019 mg/kg/dose in the bovine M. haemolytica systemic infection model, 0.55 mg/kg in the bovine P. multocida intranasal lung challenge model, 0.08 mg/kg/dose in the bovine P. multocida systemic infection model, and 0.7 mg/kg/dose in the swine A. pleuropneumoniae systemic infection model. Clinafloxacin shows good in vitro activity and efficacy in mouse models and may be a novel treatment alternative for the treatment of respiratory disease in cattle and pigs.
Synthesis of (99m)TcN-clinafloxacin Dithiocarbamate Complex and Comparative Radiobiological Evaluation in Staphylococcus aureus Infected Mice.[Pubmed:25538485]
World J Nucl Med. 2014 Sep;13(3):154-8.
Clinafloxacin dithiocarbamate (CNND) preparation and radiolabeling through [(99m)Tc identical with N](2+) core with the gamma (gamma) emitter ((99m)Tc) was assessed. The potentiality of the (99m)Tc(V) identical with N-CNND complex was investigated as perspective a Staphylococcus aureus (S.a.) in vivo infection radiotracer in terms of radiochemical stability in normal saline (n.s.), human serum (h.s.), binding efficacy with live and heat killed S.a. and biodistribution in female nude mice model (FNMD). More than 90% stability was observed in n.s. for 4 h with the highest yield of 98.70 +/- 0.26% at 30 min after reconstitution. In h.s., the (99m)Tc(V) identical with N-CNND complex was found stable up to 16 h with 15.35% side products. Maximum in vitro binding (68.75 +/- 0.80%, 90 min) with S.a. was observed after 90 min of incubation. In FNMD, (infected with live strain) approximately six-fold higher uptakes was noted in the infected to inflamed and normal muscles. The higher stability in n.s., h.s., higher S.a. (live) up take with specific and targeted in vivo distribution confirmed potentiality of the (99m)Tc(V) identical with N-CNND complex as perspective S.a. in vivo infection radiotracer.
